VitalConnect, Inc., a provider of wearable biosensor technology for wireless monitoring in hospital and remote patient populations has raised $38 million in Series C funding led by MVM and Baxter Ventures. This funding will help VitalConnect in launching the VitalConnect Platform and VitalPatch wearable biosensor in hospitals and outpatient settings across the nation.
Founded in 2011, VitalConnect combines the most sophisticated biosensor – the VitalPatch – with its comprehensive software platform. The VitalPatch is the smallest and lightest Class 2 medical device approved by the U.S. Food and Drug Administration (FDA) that measures eight different vital signs continuously and in real time, enabling unprecedented insight into patient health. The band-aid-like biosensor patch is single use and fully disposable. By allowing patients to receive quality care outside of a traditional clinical environment, VitalPatch delivers a degree of freedom and mobility that was never before possible.
“We envision a hospital of the future where inpatient and outpatient care needs integrate more seamlessly to enable a patient-centric model of care that is truly preventative and real-time. Our close of $38 million in total financing this year will help drive our continued product development and rollout,” said Nersi Nazari, CEO and founder, VitalConnect. in a statement
